A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2015
Price : $35 *
At a glance
- Drugs Elenbecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Nov 2012 New trial record
- 01 Oct 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.